Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes
摘要:
The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign. A more potent analogue, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A. Despite the development of coherent and interpretable SAIL, it was subsequently discovered that in DMSO 18 underwent an oxidation and structural rearrangement to afford the thiohydantoin 47, a compound with reduced HCV inhibitory activity. However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions containing a dimeric species 48 that exhibited potent antiviral activity. Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, symmetrical, pharmacophore realized most effectively with the stilbene 55, a compound that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.
BOURDAIS J.; OMAR A.-M. M. E., J. HETEROCYCL. CHEM., 1980, 17, NO 3, 555-558
作者:BOURDAIS J.、 OMAR A.-M. M. E.
DOI:——
日期:——
US4112100A
申请人:——
公开号:US4112100A
公开(公告)日:1978-09-05
Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes
作者:Jeffrey L. Romine、Denis R. St. Laurent、John E. Leet、Scott W. Martin、Michael H. Serrano-Wu、Fukang Yang、Min Gao、Donald R O’Boyle、Julie A. Lemm、Jin-Hua Sun、Peter T. Nower、Xiaohua (Stella) Huang、Milind S. Deshpande、Nicholas A. Meanwell、Lawrence B. Snyder
DOI:10.1021/ml1002647
日期:2011.3.10
The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign. A more potent analogue, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A. Despite the development of coherent and interpretable SAIL, it was subsequently discovered that in DMSO 18 underwent an oxidation and structural rearrangement to afford the thiohydantoin 47, a compound with reduced HCV inhibitory activity. However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions containing a dimeric species 48 that exhibited potent antiviral activity. Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, symmetrical, pharmacophore realized most effectively with the stilbene 55, a compound that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.
Bourdais, J.; Omar, A.-Mohsen M. E., Journal of Heterocyclic Chemistry, 1980, vol. 17, p. 555 - 558